Bispecific antibodies for cancer immunotherapy: Current perspectives

被引：94

作者：

Müller D. ^{[1
]}

Kontermann R.E. ^{[1
]}

机构：

[1] Institut für Zellbiologie und Immunologie, Universität Stuttgart, 70569 Stuttgart

来源：

BioDrugs | 2010年 / 24卷 / 2期

关键词：

Antibodies; general; Bispecific-antibodies; Cancer; Immunotherapies;

D O I：

10.2165/11530960-000000000-00000

中图分类号：

学科分类号：

摘要：

The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy or dual targeting approaches in order to improve binding, selectivity, and efficacy. This review summarizes recent progress in the development of bispecific antibodies and describes some new concepts developed for cancer immunotherapy. © 2010 Adis Data Information BV.

引用

页码：89 / 98

页数：9

共 60 条

[21]

Gall J.M., Davol P.A., Grabert R.C., Et al., T cells armed with anti-CD3×anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro, Exp Hematol, 33, pp. 452-459, (2005)

[22]

Dreier T., Baeuerle P.A., Fichtner I., Et al., Tcell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, J Immunol, 170, pp. 4397-4402, (2003)

[23]

Schlereth B., Quadt C., Dreier T., Et al., T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct, Cancer Immunol Immunother, 55, pp. 503-514, (2006)

[24]

Schlereth B., Kleindienst P., Fichtner I., Et al., Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bi-specific antibody construct specific for murine CD3, Cancer Immunol Immunother, 55, pp. 785-796, (2006)

[25]

Lutterbuese R., Raum T., Kischel R., Et al., Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA, J Immunother, 32, pp. 341-352, (2009)

[26]

Bargou R., Leo E., Zugmaier G., Et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, 321, pp. 974-977, (2008)

[27]

Haas C., Krinner E., Brischwein K., Et al., Mode of cytotoxic action of T cell-engaging BiTE antibody MT110, Immunobiology, 214, pp. 441-453, (2009)

[28]

Amann M., D'Argouges S., Lorenczewski G., Et al., Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release, J Immunother, 32, pp. 452-464, (2009)

[29]

Amann M., Friedrich M., Lutterbuese P., Et al., Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans, Cancer Immunol Immunother, 58, pp. 95-109, (2009)

[30]

Buhler P., Wolf P., Gierschner D., Et al., A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells, Cancer Immunol Immunother, 57, pp. 43-52, (2008)

← 1 2 3 4 5 6 →